KDM1A and sickle cell disease: In addition to their inhibition of the LSD1 catalytic activity, some LSD1 inhibitors exert scaffolding functions leading, for instance, to the removal of the NK cells lytic capacity, through a potent reduction of oxidative phosphorylation (Bailey et al., 2020a), or to the disruption of the DRED complex, with increases of γ-globin and cellular HbF contents in vitro and in vivo, useful for innovative treatment of sickle cell disease (Holshouser et al., 2020).